ATS Breathe Easy

In this episode, we have the pleasure of sitting down with Dr. Hilary DuBrock to discuss two foundational articles on pulmonary arterial hypertension treatment. We will discuss the 2013 SERAPHIN and 2015 AMBITION trials both published in the New England Journal of Medicine.

Show Notes

Show Notes

If you enjoyed this content, please follow or subscribe and leave us a review!

Access the ATS Reading List.

Recommended Reading

  1. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818. 
  2. Supplement to: Pulido T et al. 2013. 
  3. Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-844. doi:10.1056/NEJMoa1413687
  4. Supplement to: Galiè et al. 2015. 
  5. Simonneau G, Channick RN, Delcroix M, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015;46(6):1711-1720. doi:10.1183/13993003.00364-2015

Creators and Guests

JM
Host
Jennifer D. Duke, MD
Mayo Clinic
Host
P.J. Gary, MD
SUNY Upstate Medical University
HM
Guest
Hilary M. DuBrock, MD
Mayo Clinic Rochester

What is ATS Breathe Easy?

Conversations in Pulmonary, Critical Care and Sleep Medicine by the American Thoracic Society